Community protocol · Thymosin beta-4
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: Tβ4 · TB4
Sources checked: 27 August 2026
This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Quick context
Regulates cell migration and tissue processes; therapeutic applications remain largely experimental.
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Amounts, timing and cycles
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Different amounts circulate online; no regulator-confirmed safe or effective dose exists.
Profile evidence level: preclinical.
Community claims about time of day, fasting windows or training intervals are not validated clinical standards.
No individual recommendation.
Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.
No individual recommendation.
No matching detail page found in the reference source
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Reconstitution and U-100 conversion
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
Thymosin beta-4 is classified as “Endogenous actin-binding peptide”. Regulates cell migration and tissue processes; therapeutic applications remain largely experimental. This describes the investigated pathway but does not validate a community use, amount, route or combination.
This concerns effects on the cell-skeleton protein actin, which gives cells their shape and enables movement, like an internal scaffold. Researchers measure cell migration and wound closure in cell culture models.
This studies how a peptide influences the migration of cells toward an injury site, similar to workers rushing to a construction site. Speed and extent of cell migration are measured in lab models.
Researchers use controlled wound or injury models in cells or animals to study how quickly and completely tissue heals after damage. Measures typically include wound size over time and markers of new tissue formation, similar to photographing a cut each day to see how fast it closes.
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
People report perceived faster healing of injuries or tendon problems after using certain peptides, usually without a control group or objective measurement. Such individual reports do not establish actual efficacy or safety.
Personal recovery times after sports injuries while using different repair peptides are compared, often based on subjective pain scales. Such individual courses are influenced by many other factors and do not prove efficacy.
Combinations of growth-axis, mitochondrial, and skin peptides are compared here with the goal of influencing visible or felt signs of ageing, often documented personally over years. Anecdotes and vendor advertising about slowed ageing are not scientific proof.
Adverse effects and risk boundaries
Exclusion groups and professional assessment
Monitoring and laboratory markers
Evidence boundary
Therapeutic applications remain largely experimental and are not clinically confirmed.
Published evidence
Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.
Thymosin beta-4 is the endogenous protein from which the shorter fragment TB-500 is derived.
Storage and stability
Troubleshooting and error sources
Regulatory status and WADA
No FDA- or EMA-approved medicinal product; efficacy and safety are not established.
WADA 2026
This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
Frequently asked questions
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
